Assessment of Antifungal Activity of Bakuchiol on Oral-Associated Candida spp.
Table 2
Changes in the specific growth rates (µ) and the viable counts (CFU) of Candida species following bakuchiol exposure. The percentage denotes the inhibition of treated samples compared to the untreated ones.
Microorganism
Treatment
Log10 CFU/mL (%)
C. albicans ATCC 14053
Untreated
1.73 ± 0.08
10.04 ± 0.03
Bakuchiol
0.70 ± 0.07 (59.5)
7.24 ± 0.08 (27.9)
Amphotericin B
0.49 ± 0.10 (71.7)
6.64 ± 0.05 (33.9)
C. dubliniensis ATCC MYA-2975
Untreated
0.98 ± 0.14
8.32 ± 0.28
Bakuchiol
0.45 ± 0.24 (54.1)
6.87 ± 0.42 (17.4)
Amphotericin B
0.74 ± 0.19 (24.5)
7.36 ± 0.09 (11.5)
C. glabrata ATCC 90030
Untreated
1.80 ± 0.06
10.13 ± 0.08
Bakuchiol
1.11 ± 0.03 (38.3)
8.34 ± 0.07 (17.7)
Amphotericin B
1.47 ± 0.13 (18.3)
9.20 ± 0.07 (9.2)
C. krusei ATCC 14243
Untreated
0.82 ± 0.20
8.63 ± 0.45
Bakuchiol
0.73 ± 0.15 (11)
5.72 ± 0.35 (33.7)
Amphotericin B
0.55 ± 0.12 (32.9)
6.32 ± 0.21 (26.8)
C. lusitaniae ATCC 64125
Untreated
1.09 ± 0.15
8.95 ± 0.36
Bakuchiol
0.42 ± 0.10 (61.5)
6.90 ± 0.16 (22.9)
Amphotericin B
0.98 ± 0.24 (10.1)
8.69 ± 0.50 (2.9)
C. tropicalis ATCC 13803
Untreated
1.57 ± 0.14
9.80 ± 0.43
Bakuchiol
1.02 ± 0.18 (35)
9.30 ± 0.23 (5.5)
Amphotericin B
0.91 ± 0.12 (42)
8.63 ± 0.08 (11.9)
Test concentration was prepared at 0.5 × MIC. compared to the untreated samples.